Vanston Laura, Ogawa Kaleigh, Freeman Julia, Bauer Maureen, Carel Kirsten, Topoz Irina
Section of Pediatric Emergency Medicine, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.
Clinical Effectiveness, Children's Hospital Colorado, Aurora, Colo.
Pediatr Qual Saf. 2022 Mar 30;7(2):e535. doi: 10.1097/pq9.0000000000000535. eCollection 2022 Mar-Apr.
Epinephrine is the only medication that prevents morbidity and mortality in anaphylaxis. Systemic corticosteroids and H2 receptor antagonists (H2RA) may benefit select cases but are not universally indicated. This study aims to de-implement the universal use of steroids and H2RAs and emphasize epinephrine-focused care for children with anaphylaxis during acute care visits. The study aims to reduce steroid and H2RA use from 81% and 60%, respectively, to 30% by December 2019.
The primary outcome measures were the percent of patients receiving steroids and H2RAs in the emergency department (ED) or urgent care (UC). Process measure was the frequency of intravenous (IV) line placement. Balancing measures were ED/UC length of stay, admission rate, and ED/UC return visit rate. In addition, a multidisciplinary team designed the following interventions: (1) anaphylaxis clinical pathway to emphasize epinephrine-focused care, outline criteria for second-line therapies and a provider guideline for ED/UC observation; (2) standardize unit-based anaphylaxis medication kits; (3) optimize electronic medical record tools, including order sets and discharge instructions to be concordant with guideline recommendations.
The study included 870 patients. There was special cause variation in the use of steroids (81%-33%) and H2RAs (60%-11%), ED/UC Length of stay decreased (6.2-5.0 hours). There was no special cause variation in admission rates or ED/UC return visit rates.
Universal use of systemic steroids and H2RAs can be safely de-implemented in pediatric patients with anaphylaxis using quality improvement methods.
肾上腺素是唯一可预防过敏反应发病率和死亡率的药物。全身性皮质类固醇和H2受体拮抗剂(H2RA)可能对某些特定病例有益,但并非普遍适用。本研究旨在不再普遍使用类固醇和H2RA,并强调在急性护理就诊期间对过敏反应儿童进行以肾上腺素为重点的护理。该研究旨在到2019年12月将类固醇和H2RA的使用率分别从81%和60%降至30%。
主要结局指标是在急诊科(ED)或紧急护理(UC)中接受类固醇和H2RA治疗的患者百分比。过程指标是静脉输液(IV)置管的频率。平衡指标是ED/UC住院时间、住院率和ED/UC复诊率。此外,一个多学科团队设计了以下干预措施:(1)过敏反应临床路径,以强调以肾上腺素为重点的护理,概述二线治疗标准以及ED/UC观察的提供者指南;(2)标准化基于单位的过敏反应药物试剂盒;(3)优化电子病历工具,包括医嘱集和出院指导,使其与指南建议一致。
该研究纳入了870名患者。类固醇(81%-33%)和H2RA(60%-11%)的使用存在特殊原因变异,ED/UC住院时间缩短(6.2-5.0小时)。住院率或ED/UC复诊率没有特殊原因变异。
使用质量改进方法可以安全地不再对小儿过敏反应患者普遍使用全身性类固醇和H2RA。